Table 1 Adjuvant-dependent effect on antibody magnitude and durability.

From: Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate

Adjuvant

Day 42 GMT (95% CI)

Day 126 GMT (95% CI)

Day 245 GMT (95% CI)

Antibody Half-life (Days) Mean ± SEM

ASCs Mean ± SEM

Saline

A

170 (−753–2,484)

No data

No data

No data

No data

Alhydrogel

B

12,964 (7,480–19,828)

F

10,832 (6,524–19,317)

J

4,309 (–245–12,025)

N

83.20 ± 17.56

R

51.29 ± 5.30

GLA–LSQ

C

215,344 (116,529–344,931)

G

112,782 (81,772–170,943)

K

51,642 (37,037–68,597)

O

88.00 ± 10.92

S

174.30 ± 21.54

CpG in SE

D

240,581 (150,073–353,202)

H

148,935 (103,345–227,086)

L

26,803 (14,400–43,758)

P

56.40 ± 4.07

T

79.00 ± 7.23

CFA/IFA

E

36,946 (28,469–46,584)

I

27,772 (14,725–56,553)

M

13,016 (−4,132–40,895)

Q

103.50 ± 24.69

U

108.00 ± 42.67

  1. Mice were immunized with 1 μg Pfs25-EPA formulated in various adjuvants on day 0 and day 28. Sera were collected at the indicated time points and anti-Pfs25 IgG titers were determined by ELISAs. Shown is the geometric mean titer (GMT) with 95% confidence interval (CI) from 5–10 mice per group at peak titer (day 42), mid-point (day 126), and termination of the study: day 210 (CpG in SE or CFA/IFA) or day 245 (Alhydrogel and GLA-LSQ). Antibody half-lives were calculated using mid-point and end-point titers as described in the methods. Anti-Pfs25 IgG ASC numbers per million cells were calculated by ELISpots on day 245 for the Alhydrogel and GLA-LSQ groups and day 210 for the CpG in SE and CFA/IFA groups. Data are from 1 experiment and are representative of 3 similar experiments. One-way ANOVAs with Tukey post-tests were used to compare differences between anti-Pfs25 IgG titers, antibody half-lives, and the number of ASCs/million bone marrow cells. Statistically significant differences are denoted by the following: A–C (Day 42 Pfs25-EPA Saline vs Day 42 Pfs25-EPA GLA-LSQ) = ****, A–D (****), B–C (****), B–D (****), C–E (***), D–E (****), F–G (***), F–H (****), G–I (**), H–I (****), J–K (***), J–L (*), K–L (*), K–M (**), R–S (****), S–T (*), no significant differences between antibody half-lives (groups N–Q). (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Back to article page